CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip
The Philadelphia biotech reported data from 21 patients with advanced CLDN6-positive solid tumors, including 14 with platinum-resistant ovarian cancer. CEO Martin Lehr said the company remains encouraged by CTIM-76’s development as a potentially best-in-class option for patients with platinum-resistant ovarian cancer. H.C. Wainwright analyst Emily Bodnar said the initial CTIM-76 data in heavily pretreated CLDN6-positive … Read more